# IPG1094

Source: https://onco.cc/drugs/ipg1094/  
OnCo record `ipg1094` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer.

## Summary

IPG1094 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Nanjing Immunophage Biotech Co., Ltd, in metastatic cancer. Described in the registry record as a an inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: IPG1094
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a an inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of IPG1094: https://clinicaltrials.gov/search?intr=IPG1094

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients](https://onco.cc/trials/nct06212076/)

---
JSON: https://onco.cc/api/v1/entities/ipg1094.json